IL323616A - Bifunctional compounds for degradation of BRAF in the ubiquitin-proteasome pathway - Google Patents

Bifunctional compounds for degradation of BRAF in the ubiquitin-proteasome pathway

Info

Publication number
IL323616A
IL323616A IL323616A IL32361625A IL323616A IL 323616 A IL323616 A IL 323616A IL 323616 A IL323616 A IL 323616A IL 32361625 A IL32361625 A IL 32361625A IL 323616 A IL323616 A IL 323616A
Authority
IL
Israel
Prior art keywords
fluorophenyl
piperidin
sulfonamide
pyridin
methyl
Prior art date
Application number
IL323616A
Other languages
English (en)
Hebrew (he)
Inventor
Ge Peng
Jeffrey Wu
Original Assignee
Nurix Therapeutics Inc
Ge Peng
Jeffrey Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurix Therapeutics Inc, Ge Peng, Jeffrey Wu filed Critical Nurix Therapeutics Inc
Publication of IL323616A publication Critical patent/IL323616A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL323616A 2023-04-28 2025-09-28 Bifunctional compounds for degradation of BRAF in the ubiquitin-proteasome pathway IL323616A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363462918P 2023-04-28 2023-04-28
PCT/US2024/026679 WO2024227104A1 (fr) 2023-04-28 2024-04-26 Composés bifonctionnels pour dégrader le braf par l'intermédiaire d'une voie ubiquitine-protéosome

Publications (1)

Publication Number Publication Date
IL323616A true IL323616A (en) 2025-11-01

Family

ID=91376068

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323616A IL323616A (en) 2023-04-28 2025-09-28 Bifunctional compounds for degradation of BRAF in the ubiquitin-proteasome pathway

Country Status (8)

Country Link
EP (1) EP4702014A1 (fr)
JP (1) JP2026517764A (fr)
KR (1) KR20260005915A (fr)
CN (1) CN121548574A (fr)
AU (1) AU2024260700A1 (fr)
IL (1) IL323616A (fr)
MX (1) MX2025012819A (fr)
WO (1) WO2024227104A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3867242A1 (fr) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome
EP3924350A1 (fr) 2019-02-13 2021-12-22 Nurix Therapeutics, Inc. Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome
CA3160713A1 (fr) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Composes bifonctionnels pour la degradation de la btk par l'intermediaire de la voie de l'ubiquitine-proteosome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112812109B (zh) * 2019-11-18 2022-06-21 中国科学院微生物研究所 化合物DaP-01及其制备方法和应用
EP4232023A4 (fr) * 2020-10-26 2025-11-12 Dana Farber Cancer Inst Inc Composés pour la dégradation ciblée de protéines de kinases
MX2023012981A (es) * 2021-05-03 2024-01-11 Nurix Therapeutics Inc Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.

Also Published As

Publication number Publication date
AU2024260700A1 (en) 2025-11-13
EP4702014A1 (fr) 2026-03-04
KR20260005915A (ko) 2026-01-12
MX2025012819A (es) 2025-12-01
CN121548574A (zh) 2026-02-17
JP2026517764A (ja) 2026-06-02
WO2024227104A1 (fr) 2024-10-31

Similar Documents

Publication Publication Date Title
JP7741282B2 (ja) ユビキチンプロテオソーム経路を介してbtkを分解するための二官能性化合物
US12600732B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US20230158151A1 (en) Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
US20240279202A1 (en) Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
KR20260005915A (ko) 유비퀴틴-프로테아좀 경로를 통한 braf 분해용 이중기능 화합물
US20250002489A1 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
WO2025111513A1 (fr) Composés utiles dans la modulation de l'activité de klhdc1 et de klhdc2
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma
HK40081936A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway